BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio's acquisition of all of the outstanding shares of Eidos common stock that BridgeBio does not already own. The merger is expected to close on or about January 26, 2021, subject to the satisfaction or waiver of other conditions to closing.

Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.

Here's why the biggest biotech IPO of 2019 outshines all its peers.

My Best Biotech Stock for 2021

Editas Medicine

Fate Therapeutics

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

3 Biotech Stocks That Could Double Your Money in 2021

PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio's proposed merger with Eidos and each of the other proposals to be considered at both companies' virtual special meetings to be held on January 19, 2021.

Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger

SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.

UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases

Adaptive Biotechnologies

Boston Scientific

Centene

Thermo Fisher Scientific

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adaptive Biotechnologies Corp. (NASDAQ:ADPT), Centene Corp. (NYSE:CNC), BridgeBio Pharma Inc. (NASDAQ:BBIO), Boston Scientific Corp. (NYSE:BSX) and Thermo Fisher Scientific Inc. (NYSE:TMO). This week, Halvorsen revealed a slight reduction to his Adaptive Biotechnologies position according to GuruFocus Real-Time Picks, which is also a Premium feature.

Andreas Halvorsen's Top 5 Health Care Positions as of the 3rd Quarter

Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise

BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease

This company's about to begin delivering a stream of new drugs that target genetic diseases, and hardly anyone's heard about it.

Got $5,000 and 5 Years to Wait? Buy This Under-the-Radar Biotech Stock Now

WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches of fiduciary duties and other violations of law related to BridgeBio's agreement to merge with Eidos Therapeutics, Inc. (“Eidos”). Under the terms of the agreement, BridgeBio will issue either $73.26 in cash or 1.85 shares of BridgeBio common stock to shareholders of Eidos.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BridgeBio Pharma, Inc. Merger

•  Application accepted under P riority R eview designation •  Application accepted into Real Time Oncology Review (RTOR) pilot program •  This is BridgeBio's s econd NDA a cceptance •  Application will also be submitted for review in Australia and Canada under Project Orbis

BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma

SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor (BBP-398) in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes. BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division.

BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations

China Grand Pharma announced a $340 million agreement to develop and commercialize Telix Pharma's molecularly-targeted radiation products in China. JW Therapeutics, a Shanghai cell therapy company, raised $300 million in its Hong Kong IPO at a market capitalization of $1 billion.

Week In Review: 3 $300 Million Deals For China Biopharma

-Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio's clinical and commercial development infrastructure to bear upon Eidos' Acoramidis 

BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: BridgeBio Pharma (BBIO) Q3 Earnings Expected to Decline

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Phoenix Tissue Repair today announced that the first patient has been dosed in a Phase 2 study of BBP-589 (also known as PTR-01), an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a rare genetic disorder caused by mutations in the gene encoding collagen type VII (C7).

BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

PALO ALTO, Calif. and DENVER, Oct. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus today announced a collaboration to advance novel research on genetically driven diseases into therapeutic applications for patients.

BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases

LA JOLLA and PALO ALTO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- The Salk Institute and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced a three-year collaboration agreement formed to advance cutting-edge academic discoveries in genetically driven diseases toward therapeutic applications. Under the partnership, BridgeBio will help fund research programs from Salk's world-renowned innovative cancer research, with the eventual goal of developing new therapeutics for patients in need.

Salk Institute and BridgeBio Pharma Collaborate to Advance Therapies for Genetically Driven Disease

Eidos Therapeutics Inc

BridgeBio announced plans to fully acquire the biotech.

Why Eidos Therapeutics Stock Is Skyrocketing Today

New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/65213_5134e5c474e31b01_001full.jpgTo: All Persons or Entitie

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of BridgeBio Pharma, Inc. with Eidos Therapeutics, Inc. is Fair to BBIO Shareholders

BridgeBio Pharma Inc (NASDAQ: BBIO) said on Monday that it will increase its stake in Eidos Therapeutics Inc (NASDAQ: EIDX) by 36.3% in a cash deal that is valued at £134.95 million (aggregate maximum). At £30.54 per share, BridgeBio Pharma is currently 20% up year to date in the stock market after recovering from a low of £12.42 per share in March.

BridgeBio Pharma to increase its stake in Eidos Therapeutics by 36.3%

BridgeBio Pharma Inc. BBIO, announced Monday an agreement to buy Eidos Therapeutics Inc. EIDX, -0.30% in a deal that values Eidos at about $2.83 billion. Eidos's stock is currently halted for news, and BridgeBio shares are still untraded.

BridgeBio to buy Eidos Therapeutics in a cash and stock deal valuing Eidos at $2.8 billion

BridgeBio to Acquire All Outstanding Shares of E idos it Does Not Already Own

BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement

Axovant Gene Therapies Ltd

Sio Gene Therapies

These underappreciated biotechnology start-ups could turn heads one day -- but not yet.

2 Under-the-Radar Biotech Stocks You'll Wish You Didn't Ignore

BridgeBio Pharma said the FDA accepted its New Drug Application, the first NDA for the company, for its therapy to treat a rare, at times fatal, disease that often targets infants. BBIO rose.

BridgeBio Pharma Gets FDA OK For New Drug Application; BBIO Stock Up

Application accepted under Priority Review designation with Breakthrough Therapy  Designation  and  Rare Pediatric Disease Designation previously granted

BridgeBio Pharma and Affiliate Origin Biosciences Announces FDA Acceptance of its New Drug Application for Fosdenopterin for the Treatment of MoCD Type A

News for BridgeBio Pharma Inc Stock (BBIO)